M. McCue

发表

A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia

J. Affinito, P. Goldsmith, A. Mahableshwarkar, 2019, Schizophrenia Research.

Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

S. Parikh, C. François, A. Eramo, 2021, BMC Psychiatry.

Benefits of Oral Supplementation With and Without Synbiotics in Young Children With Acute Bacterial Infections

J. Schrezenmeir, G. Comer, P. Alarcón, 2004, Clinical pediatrics.

Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support Program

J. Manjelievskaia, M. Touya, M. McCue, 2021, Current medical research and opinion.

Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis*

S. Wang-Weigand, M. McCue, F. Ogrinc, 2009 .

Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis.

S. Wang-Weigand, M. McCue, F. Ogrinc, 2009, Current medical research and opinion.

Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study

B. Fehnert, R. Khatib, A. Eramo, 2022, JMIR formative research.

Effect of Nucleotides on Diarrhea and Immune Responses in Healthy Term Infants in Taiwan

Y. Chou, F. Huang, Walter Chen, 2003, Journal of pediatric gastroenterology and nutrition.

Wearable Technology for High-Frequency Cognitive and Mood Assessment in Major Depressive Disorder: Longitudinal Observational Study

Nick Taptiklis, Jennifer H Barnett, Caroline Skirrow, 2019, JMIR mental health.

High-frequency cognitive and mood assessment in major depressive disorder with wearable technology (Preprint)

B. Fehnert, J. Barnett, C. Skirrow, 2018 .

Adapting the Goal Attainment Approach for Major Depressive Disorder

S. Parikh, M. Opler, C. François, 2019, Neurology and Therapy.

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events

J. Affinito, J. Xie, P. Goldsmith, 2017, Drugs in R&D.

Design and Implementation of a Digitally Enabled Care Pathway to Improve Management of Depression in a Large Health Care System: Protocol for the Implementation of a Patient Care Platform

B. Fehnert, D. Kemp, R. Khatib, 2023, JMIR research protocols.

An App-Based Digit Symbol Substitution Test for Assessment of Cognitive Deficits in Adults With Major Depressive Disorder: Evaluation Study

Nelson B Rodrigues, R. McIntyre, B. Fehnert, 2022, JMIR mental health.

User-Centered Design of a Digitally Enabled Care Pathway in a Large Health System: Qualitative Interview Study

B. Fehnert, R. Khatib, James King, 2023, JMIR human factors.

Correction: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

S. Parikh, C. François, A. Eramo, 2022, BMC Psychiatry.

Patient attitudes toward and goals for MDD treatment: a survey study

M. Opler, C. François, A. Eramo, 2019, Patient preference and adherence.

Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey

R. McIntyre, S. Parikh, M. Opler, 2023, BMC Psychiatry.

Longitudinal study to assess antidepressant treatment patterns and outcomes in individuals with depression in the general population.

A. Krystal, M. Ohayon, M. McCue, 2022, Journal of affective disorders.